Christopher M. Cimarusti

Biography

Dr. Christopher Cimarusti has vast leadership experience in pharmaceutical discovery, development and manufacturing at Squibb Corporation and Bristol-Myers Squibb. As a discovery chemist, Dr. Cimarusti synthesized the antihypertensive nadolol and the antibiotic aztreonam for the first time and designed their commercial processes. As a discovery leader, he co-led the antibiotic effort with Richard Sykes and became Director of Organic Chemistry for the Squibb Institute for Medical Research. Subsequently, he was responsible for all biological and chemical process development within Squibb Corporation, including technology transfer directly to manufacturing, monitoring ongoing production and optimization of existing processes. After the merger, he became Vice President of Process R&D within the Pharmaceutical Research Institute. He led a team that examined early development productivity and strategies were developed and implemented that led to a new paradigm for these activities. He was appointed Senior Vice President, Pharmaceutical Development and led a global staff of 1,200 engaged in the CMC disciplines for small and large molecules. He also had responsibility for global Clinical Supply Operations, Project Management and Portfolio Management. He was a member of the Institute Executive Committee and a co-leader and/or member of operating committees that oversaw exploratory development, full development and life-cycle management, and technology transfer. Dr. Cimarusti led the Executive-Committee commissioned "Approval Process Study", whose recommendations have contributed significantly to the recent success of BMS with new product approvals.

Research Interest

Dr. Christopher Cimarusti has vast leadership experience in pharmaceutical discovery, development and manufacturing at Squibb Corporation and Bristol-Myers Squibb. As a discovery chemist, Dr. Cimarusti synthesized the antihypertensive nadolol and the antibiotic aztreonam for the first time and designed their commercial processes. As a discovery leader, he co-led the antibiotic effort with Richard Sykes and became Director of Organic Chemistry for the Squibb Institute for Medical Research. Subsequently, he was responsible for all biological and chemical process development within Squibb Corporation, including technology transfer directly to manufacturing, monitoring ongoing production and optimization of existing processes. After the merger, he became Vice President of Process R&D within the Pharmaceutical Research Institute. He led a team that examined early development productivity and strategies were developed and implemented that led to a new paradigm for these activities. He was appointed Senior Vice President, Pharmaceutical Development and led a global staff of 1,200 engaged in the CMC disciplines for small and large molecules. He also had responsibility for global Clinical Supply Operations, Project Management and Portfolio Management. He was a member of the Institute Executive Committee and a co-leader and/or member of operating committees that oversaw exploratory development, full development and life-cycle management, and technology transfer. Dr. Cimarusti led the Executive-Committee commissioned "Approval Process Study", whose recommendations have contributed significantly to the recent success of BMS with new product approvals.